> top > docs > PubMed:9792861 > annotations

PubMed:9792861 JSONTXT

Annnotations TAB JSON ListView MergeView

NCBI-Disease-Corpus-GPT5-withguidelines

Id Subject Object Predicate Lexical cue
T1 53-78 Modifier denotes breast and ovarian cancer
T2 138-151 Modifier denotes breast cancer
T3 210-223 Modifier denotes breast cancer
T4 228-249 Modifier denotes breast/ovarian cancer
T5 355-361 Modifier denotes cancer
T6 806-820 SpecificDisease denotes ovarian cancer
T7 965-978 SpecificDisease denotes breast cancer
T8 1027-1040 Modifier denotes breast cancer
T9 1450-1463 Modifier denotes breast cancer
T10 1468-1489 Modifier denotes breast/ovarian cancer

NCBI-Disease-Corpus-GPT5-noguidelines

Id Subject Object Predicate Lexical cue
T1 53-78 CompositeMention denotes breast and ovarian cancer
T2 138-151 SpecificDisease denotes breast cancer
T3 210-223 SpecificDisease denotes breast cancer
T4 228-249 CompositeMention denotes breast/ovarian cancer
T5 355-361 DiseaseClass denotes cancer
T6 806-820 SpecificDisease denotes ovarian cancer
T7 965-978 SpecificDisease denotes breast cancer
T8 1027-1040 SpecificDisease denotes breast cancer
T9 1450-1463 SpecificDisease denotes breast cancer
T10 1468-1489 CompositeMention denotes breast/ovarian cancer

NCBI-Disease-Corpus-GPT5-guidelineprompt

Id Subject Object Predicate Lexical cue
T1 53-78 CompositeMention denotes breast and ovarian cancer
T2 138-151 Modifier denotes breast cancer
T3 210-249 CompositeMention denotes breast cancer and breast/ovarian cancer
T4 355-361 Modifier denotes cancer
T5 806-820 SpecificDisease denotes ovarian cancer
T6 965-978 SpecificDisease denotes breast cancer
T7 1027-1040 Modifier denotes breast cancer
T8 1450-1489 CompositeMention denotes breast cancer and breast/ovarian cancer

NCBI-Disease-Corpus-Moderated1

Id Subject Object Predicate Lexical cue
T1 53-78 CompositeMention denotes breast and ovarian cancer
T2 138-151 Modifier denotes breast cancer
T3 210-223 Modifier denotes breast cancer
T4 228-249 CompositeMention denotes breast/ovarian cancer
T5 355-361 Modifier denotes cancer
T6 806-820 SpecificDisease denotes ovarian cancer
T7 965-978 SpecificDisease denotes breast cancer
T8 1027-1040 Modifier denotes breast cancer
T9 1450-1463 Modifier denotes breast cancer
T10 1468-1489 CompositeMention denotes breast/ovarian cancer

DisGeNET

Id Subject Object Predicate Lexical cue
T0 8-13 gene:672 denotes BRCA1
T1 64-78 disease:C0029925 denotes ovarian cancer
T2 8-13 gene:672 denotes BRCA1
T3 64-78 disease:C1140680 denotes ovarian cancer
T4 18-23 gene:675 denotes BRCA2
T5 64-78 disease:C0029925 denotes ovarian cancer
T6 18-23 gene:675 denotes BRCA2
T7 64-78 disease:C1140680 denotes ovarian cancer
R1 T0 T1 associated_with BRCA1,ovarian cancer
R2 T2 T3 associated_with BRCA1,ovarian cancer
R3 T4 T5 associated_with BRCA2,ovarian cancer
R4 T6 T7 associated_with BRCA2,ovarian cancer

NCBIDiseaseCorpus

Id Subject Object Predicate Lexical cue
T1 53-78 Modifier:D061325 denotes breast and ovarian cancer
T2 138-151 Modifier:D001943 denotes breast cancer
T3 210-223 Modifier:D001943 denotes breast cancer
T4 228-249 Modifier:D061325 denotes breast/ovarian cancer
T5 355-361 Modifier:D009369 denotes cancer
T6 806-820 SpecificDisease:D010051 denotes ovarian cancer
T7 965-978 SpecificDisease:D001943 denotes breast cancer
T8 1027-1040 Modifier:D001943 denotes breast cancer
T9 1450-1463 Modifier:D001943 denotes breast cancer
T10 1468-1489 Modifier:D061325 denotes breast/ovarian cancer

NCBI-Disease-Test

Id Subject Object Predicate Lexical cue database_id
T154 53-78 Modifier denotes breast and ovarian cancer D061325
T155 138-151 Modifier denotes breast cancer D001943
T156 210-223 Modifier denotes breast cancer D001943
T157 228-249 Modifier denotes breast/ovarian cancer D061325
T158 355-361 Modifier denotes cancer D009369
T159 806-820 SpecificDisease denotes ovarian cancer D010051
T160 965-978 SpecificDisease denotes breast cancer D001943
T161 1027-1040 Modifier denotes breast cancer D001943
T162 1450-1463 Modifier denotes breast cancer D001943
T163 1468-1489 Modifier denotes breast/ovarian cancer D061325

NCBI-Disease-Test-Assistant-Knowledge

Id Subject Object Predicate Lexical cue
T1 8-13 SpecificDisease denotes BRCA1
T2 18-23 SpecificDisease denotes BRCA2
T3 53-78 CompositeMention denotes breast and ovarian cancer
T4 138-151 SpecificDisease denotes breast cancer
T5 174-179 SpecificDisease denotes BRCA1
T6 184-189 SpecificDisease denotes BRCA2
T7 210-223 SpecificDisease denotes breast cancer
T8 228-249 CompositeMention denotes breast/ovarian cancer
T9 355-361 DiseaseClass denotes cancer
T10 518-539 SpecificDisease denotes BRCA1 C4446T mutation
T11 592-616 SpecificDisease denotes BRCA2 8765delAG mutation
T12 748-763 SpecificDisease denotes BRCA1 mutations
T13 806-820 SpecificDisease denotes ovarian cancer
T14 895-910 SpecificDisease denotes BRCA2 mutations
T15 965-978 SpecificDisease denotes breast cancer
T16 1027-1040 SpecificDisease denotes breast cancer
T17 1371-1376 SpecificDisease denotes BRCA1
T18 1381-1386 SpecificDisease denotes BRCA2
T19 1450-1463 SpecificDisease denotes breast cancer
T20 1468-1489 CompositeMention denotes breast/ovarian cancer

NCBI-Disease-Test-4o-NoGuidelineInPrompt

Id Subject Object Predicate Lexical cue
T1 53-78 CompositeMention denotes breast and ovarian cancer
T2 138-166 DiseaseClass denotes breast cancer-susceptibility
T3 210-223 SpecificDisease denotes breast cancer
T4 228-249 CompositeMention denotes breast/ovarian cancer
T5 355-361 DiseaseClass denotes cancer
T6 806-820 SpecificDisease denotes ovarian cancer
T7 965-978 SpecificDisease denotes breast cancer
T8 1027-1040 SpecificDisease denotes breast cancer
T9 1450-1463 SpecificDisease denotes breast cancer
T10 1468-1489 CompositeMention denotes breast/ovarian cancer

NCBI-Disease-Corpus-o3-2

Id Subject Object Predicate Lexical cue
T1 53-78 CompositeMention denotes breast and ovarian cancer
T2 210-223 Modifier denotes breast cancer
T3 228-249 CompositeMention denotes breast/ovarian cancer
T4 806-820 Modifier denotes ovarian cancer
T5 965-978 Modifier denotes breast cancer
T6 1027-1040 Modifier denotes breast cancer
T7 1450-1463 Modifier denotes breast cancer
T8 1468-1489 CompositeMention denotes breast/ovarian cancer

NCBI-Disease-Corpus-high-o3-1

Id Subject Object Predicate Lexical cue
T1 64-78 Modifier denotes ovarian cancer
T2 210-223 Modifier denotes breast cancer
T3 228-249 Modifier denotes breast/ovarian cancer
T4 806-820 Modifier denotes ovarian cancer
T5 965-978 Modifier denotes breast cancer
T6 1027-1040 Modifier denotes breast cancer

NCBI-Disease-Corpus-high-o3-2

Id Subject Object Predicate Lexical cue
T1 53-78 CompositeMention denotes breast and ovarian cancer
T2 138-151 Modifier denotes breast cancer
T3 210-223 SpecificDisease denotes breast cancer
T4 228-249 CompositeMention denotes breast/ovarian cancer
T5 806-820 SpecificDisease denotes ovarian cancer
T6 965-978 SpecificDisease denotes breast cancer
T7 1027-1040 SpecificDisease denotes breast cancer
T8 1450-1463 SpecificDisease denotes breast cancer
T9 1468-1489 CompositeMention denotes breast/ovarian cancer

NCBI-Disease-Test-4o-GuidelineInPrompt

Id Subject Object Predicate Lexical cue
T1 53-78 Modifier denotes breast and ovarian cancer
T2 138-151 Modifier denotes breast cancer
T3 210-223 Modifier denotes breast cancer
T4 228-249 Modifier denotes breast/ovarian cancer
T5 355-361 Modifier denotes cancer
T6 806-820 SpecificDisease denotes ovarian cancer
T7 965-978 SpecificDisease denotes breast cancer
T8 1027-1040 SpecificDisease denotes breast cancer
T9 1450-1463 Modifier denotes breast cancer
T10 1468-1489 Modifier denotes breast/ovarian cancer

NCBI-Disease-Corpus-UpdatedGuideline

Id Subject Object Predicate Lexical cue
T1 8-33 CompositeMention denotes BRCA1 and BRCA2 mutations
T2 53-87 CompositeMention denotes breast and ovarian cancer families
T3 138-172 DiseaseClass denotes breast cancer-susceptibility genes
T4 174-179 SpecificDisease denotes BRCA1
T5 184-189 SpecificDisease denotes BRCA2
T6 210-223 SpecificDisease denotes breast cancer
T7 228-258 CompositeMention denotes breast/ovarian cancer families
T8 355-370 DiseaseClass denotes cancer families
T9 518-539 SpecificDisease denotes BRCA1 C4446T mutation
T10 592-616 SpecificDisease denotes BRCA2 8765delAG mutation
T11 748-763 SpecificDisease denotes BRCA1 mutations
T12 806-820 SpecificDisease denotes ovarian cancer
T13 895-910 SpecificDisease denotes BRCA2 mutations
T14 965-978 SpecificDisease denotes breast cancer
T15 1027-1040 SpecificDisease denotes breast cancer
T16 1371-1396 CompositeMention denotes BRCA1 and BRCA2 mutations
T17 1450-1463 SpecificDisease denotes breast cancer
T18 1468-1498 CompositeMention denotes breast/ovarian cancer families

NCBI-Disease-Corpus-humanintheloop

Id Subject Object Predicate Lexical cue
T1 53-1463 Modifier denotes breast and ovarian cancer families. We have identified four mutations in each of the breast cancer-susceptibility genes, BRCA1 and BRCA2, in French Canadian breast cancer and breast/ovarian cancer families from Quebec. To identify founder effects, we examined independently ascertained French Canadian cancer families for the distribution of these eight mutations. Mutations were found in 41 of 97 families. Six of eight mutations were observed at least twice. The BRCA1 C4446T mutation was the most common mutation found, followed by the BRCA2 8765delAG mutation. Together, these mutations were found in 28 of 41 families identified to have a mutation. The odds of detection of any of the four BRCA1 mutations was 18.7x greater if one or more cases of ovarian cancer were also present in the family. The odds of detection of any of the four BRCA2 mutations was 5.3x greater if there were at least five cases of breast cancer in the family. Interestingly, the presence of a breast cancer case <36 years of age was strongly predictive of the presence of any of the eight mutations screened. Carriers of the same mutation, from different families, shared similar haplotypes, indicating that the mutant alleles were likely to be identical by descent for a mutation in the founder population. The identification of common BRCA1 and BRCA2 mutations will facilitate carrier detection in French Canadian breast cancer
T2 1475-1489 Modifier denotes ovarian cancer

NCBI-Disease-Corpus-rezarta1

Id Subject Object Predicate Lexical cue
T1 53-1463 SpecificDisease denotes breast and ovarian cancer families. We have identified four mutations in each of the breast cancer-susceptibility genes, BRCA1 and BRCA2, in French Canadian breast cancer and breast/ovarian cancer families from Quebec. To identify founder effects, we examined independently ascertained French Canadian cancer families for the distribution of these eight mutations. Mutations were found in 41 of 97 families. Six of eight mutations were observed at least twice. The BRCA1 C4446T mutation was the most common mutation found, followed by the BRCA2 8765delAG mutation. Together, these mutations were found in 28 of 41 families identified to have a mutation. The odds of detection of any of the four BRCA1 mutations was 18.7x greater if one or more cases of ovarian cancer were also present in the family. The odds of detection of any of the four BRCA2 mutations was 5.3x greater if there were at least five cases of breast cancer in the family. Interestingly, the presence of a breast cancer case <36 years of age was strongly predictive of the presence of any of the eight mutations screened. Carriers of the same mutation, from different families, shared similar haplotypes, indicating that the mutant alleles were likely to be identical by descent for a mutation in the founder population. The identification of common BRCA1 and BRCA2 mutations will facilitate carrier detection in French Canadian breast cancer
T2 1475-1489 SpecificDisease denotes ovarian cancer

NCBI-Disease-Corpus-All

Id Subject Object Predicate Lexical cue database_id
T154 53-78 Modifier denotes breast and ovarian cancer D061325
T155 138-151 Modifier denotes breast cancer D001943
T156 210-223 Modifier denotes breast cancer D001943
T157 228-249 Modifier denotes breast/ovarian cancer D061325
T158 355-361 Modifier denotes cancer D009369
T159 806-820 SpecificDisease denotes ovarian cancer D010051
T160 965-978 SpecificDisease denotes breast cancer D001943
T161 1027-1040 Modifier denotes breast cancer D001943
T162 1450-1463 Modifier denotes breast cancer D001943
T163 1468-1489 Modifier denotes breast/ovarian cancer D061325

NCBI-Disease-Corpus-2stage-All

Id Subject Object Predicate Lexical cue
T1 53-78 Modifier denotes breast and ovarian cancer
T2 138-151 Modifier denotes breast cancer
T3 210-223 Modifier denotes breast cancer
T4 228-249 CompositeMention denotes breast/ovarian cancer
T5 355-361 Modifier denotes cancer
T6 806-820 SpecificDisease denotes ovarian cancer
T7 965-978 SpecificDisease denotes breast cancer
T8 1027-1040 SpecificDisease denotes breast cancer
T9 1450-1463 Modifier denotes breast cancer
T10 1468-1489 CompositeMention denotes breast/ovarian cancer

NCBI-Disease-Corpus-rezarta-All

Id Subject Object Predicate Lexical cue
T1 53-1463 Modifier denotes breast and ovarian cancer families. We have identified four mutations in each of the breast cancer-susceptibility genes, BRCA1 and BRCA2, in French Canadian breast cancer and breast/ovarian cancer families from Quebec. To identify founder effects, we examined independently ascertained French Canadian cancer families for the distribution of these eight mutations. Mutations were found in 41 of 97 families. Six of eight mutations were observed at least twice. The BRCA1 C4446T mutation was the most common mutation found, followed by the BRCA2 8765delAG mutation. Together, these mutations were found in 28 of 41 families identified to have a mutation. The odds of detection of any of the four BRCA1 mutations was 18.7x greater if one or more cases of ovarian cancer were also present in the family. The odds of detection of any of the four BRCA2 mutations was 5.3x greater if there were at least five cases of breast cancer in the family. Interestingly, the presence of a breast cancer case <36 years of age was strongly predictive of the presence of any of the eight mutations screened. Carriers of the same mutation, from different families, shared similar haplotypes, indicating that the mutant alleles were likely to be identical by descent for a mutation in the founder population. The identification of common BRCA1 and BRCA2 mutations will facilitate carrier detection in French Canadian breast cancer
T2 1475-1489 Modifier denotes ovarian cancer

NCBI-Disease-Corpus-4oGuideline-All

Id Subject Object Predicate Lexical cue
T1 8-33 DiseaseClass denotes BRCA1 and BRCA2 mutations
T2 37-78 Modifier denotes French Canadian breast and ovarian cancer
T3 138-151 Modifier denotes breast cancer
T4 194-223 Modifier denotes French Canadian breast cancer
T5 228-249 CompositeMention denotes breast/ovarian cancer
T6 339-361 Modifier denotes French Canadian cancer
T7 806-820 SpecificDisease denotes ovarian cancer
T8 965-978 SpecificDisease denotes breast cancer
T9 1027-1040 SpecificDisease denotes breast cancer
T10 1434-1463 Modifier denotes French Canadian breast cancer
T11 1468-1489 CompositeMention denotes breast/ovarian cancer

NCBI-Disease-Corpus-Simple-All

Id Subject Object Predicate Lexical cue
T1 53-78 CompositeMention denotes breast and ovarian cancer
T2 138-151 SpecificDisease denotes breast cancer
T3 210-223 SpecificDisease denotes breast cancer
T4 228-249 CompositeMention denotes breast/ovarian cancer
T5 355-361 SpecificDisease denotes cancer
T6 806-820 SpecificDisease denotes ovarian cancer
T7 965-978 SpecificDisease denotes breast cancer
T8 1027-1040 SpecificDisease denotes breast cancer
T9 1450-1463 SpecificDisease denotes breast cancer
T10 1468-1489 CompositeMention denotes breast/ovarian cancer

123456

Id Subject Object Predicate Lexical cue
T1 53-223 Modifier denotes breast and ovarian cancer families. We have identified four mutations in each of the breast cancer-susceptibility genes, BRCA1 and BRCA2, in French Canadian breast cancer
T2 235-249 Modifier denotes ovarian cancer
T4 1450-1463 Modifier denotes breast cancer
T5 1468-1489 Modifier denotes breast/ovarian cancer

12345

Id Subject Object Predicate Lexical cue
T1 53-223 DiseaseClass denotes breast and ovarian cancer families. We have identified four mutations in each of the breast cancer-susceptibility genes, BRCA1 and BRCA2, in French Canadian breast cancer
T2 235-249 DiseaseClass denotes ovarian cancer
T4 1450-1463 DiseaseClass denotes breast cancer
T5 1468-1489 CompositeMention denotes breast/ovarian cancer